Synthesis of potent water-soluble tissue transglutaminase inhibitors.
about
Transglutaminase is a tumor cell and cancer stem cell survival factorCeliac Disease-Specific TG2-Targeted Autoantibodies Inhibit Angiogenesis Ex Vivo and In Vivo in Mice by Interfering with Endothelial Cell DynamicsA novel extracellular role for tissue transglutaminase in matrix-bound VEGF-mediated angiogenesis.Transamidase site-targeted agents alter the conformation of the transglutaminase cancer stem cell survival protein to reduce GTP binding activity and cancer stem cell survival.The role of TG2 in regulating S100A4-mediated mammary tumour cell migrationThioredoxin is involved in endothelial cell extracellular transglutaminase 2 activation mediated by celiac disease patient IgA.Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling.Tissue transglutaminase (TG2) enables survival of human malignant pleural mesothelioma cells in hypoxia.Potential of transglutaminase 2 as a therapeutic target.TG2, a novel extracellular protein with multiple functions.Recent advances in the development of tissue transglutaminase (TG2) inhibitors.Transglutaminase as a therapeutic target for celiac disease.Transglutaminase inhibitors: a patent review.Immunopathogenesis and therapeutic approaches in pediatric celiac disease.Strategies towards in vivo imaging of active transglutaminase type 2 using positron emission tomography.Pituitary adenylate cyclase-activating polypeptide type 1 receptor (PAC1) gene is suppressed by transglutaminase 2 activation.Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor.Involvement of cell surface TG2 in the aggregation of K562 cells triggered by gluten.The role of TG2 in ECV304-related vasculogenic mimicry.The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.The functional relationship between transglutaminase 2 and transforming growth factor β1 in the regulation of angiogenesis and endothelial-mesenchymal transition.Epithelial transport and deamidation of gliadin peptides: a role for coeliac disease patient immunoglobulin A.Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide.Do changes in transglutaminase activity alter latent transforming growth factor beta activation in experimental diabetic nephropathy?Indwelling catheters and medical implants with FXIIIa inhibitors: A novel approach to the treatment of catheter and medical device-related infections.Celiac disease patient IgA antibodies induce endothelial adhesion and cell polarization defects via extracellular transglutaminase 2.An extracellular transglutaminase is required for apple pollen tube growth.Synthesis and Kinetic Characterisation of Water-Soluble Fluorogenic Acyl Donors for Transglutaminase 2.Simulated environmental criticalities affect transglutaminase of Malus and Corylus pollens having different allergenic potentialAre Transglutaminase 2 Inhibitors Able to Reduce Gliadin-Induced Toxicity Related to Celiac Disease? A Proof-of-Concept StudyTargeted delivery of a novel group of site-directed transglutaminase inhibitors to the liver using liposomes: a new approach for the potential treatment of liver fibrosisInhibition of transglutaminase 2 enzymatic activity ameliorates the anti-angiogenic effects of coeliac disease autoantibodies
P2860
Q26799862-6C23B310-4AF2-4B2C-81BF-A95AF68AF877Q27316086-2894DB0A-893D-45B1-BA91-27777975CF10Q30547848-7279180E-DE02-4C38-BCA0-878E99A8E6D9Q33728989-F3D86FFA-A176-4AF8-9980-C893A60EA4CDQ34613001-6A969FAC-B0FF-4928-93AC-1B74FB869477Q35018831-672D9CB7-B77F-4357-8DFD-5402429D4127Q35921509-F082CD0E-005A-4E26-9856-F5625F4EB446Q37745215-C60F05B7-4F5B-44E0-AB82-3B54ED4C1396Q37776508-8C5FC55A-D0AA-47A1-8409-1D9D23F54CB1Q37912042-781567AC-83B0-4806-A9D4-3D6563103AD0Q37967368-31A1CC2E-377B-4D8C-85CC-D87D0EE291AEQ38269678-C6DD413C-CBA7-4089-A770-D1F412FE8224Q38631307-EC20264A-E0B4-4110-825A-BF2ECCC1F360Q38783192-043C86B1-29E0-4A0C-A76B-4848AC8BDCEBQ38886629-947430DE-1CE2-4A82-8678-85EF87C8268DQ39094479-15FF0B25-0F0F-44C3-8788-41667DC4FD43Q39162858-7AC72C39-52AB-4D38-BB41-21B3B1B4D5C9Q39325700-75C5FF44-A314-4303-90E8-94FCF884ABB3Q39414670-C624A388-90DD-4B36-95C8-F0ECAD7B6792Q39636385-48AEE542-AB50-4011-8580-1281827CA466Q42261474-BDF96E36-833D-4293-BD87-5E7354D592BBQ42482567-A60A1C07-6450-4C4E-86C9-582A252145E7Q42683546-07FBE48D-10B9-434E-A06B-B4FA83BC907BQ42826363-B8BE6EB7-CEE5-4D9A-B489-D911BCC4232FQ43165728-3E037938-0578-4379-94A0-B3B2D2AA11EBQ47685543-C92B7EA7-C700-4042-A9CB-4619F23724E3Q50554531-EF0C9D32-E33B-424B-929B-F148AD25FB94Q53764493-63470A73-AB4E-4128-BB59-72B96F023254Q56982661-4770A935-EE20-4A53-B374-17FE087EDE0BQ57937529-D0854655-05F3-440D-BCF1-BF228970ECE4Q57937571-6DC1A390-2898-4BBA-9823-714AAFDF2FA3Q57937600-8F14EAAA-E51E-44DD-AC1F-D780933BF06C
P2860
Synthesis of potent water-soluble tissue transglutaminase inhibitors.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Synthesis of potent water-soluble tissue transglutaminase inhibitors.
@ast
Synthesis of potent water-soluble tissue transglutaminase inhibitors.
@en
type
label
Synthesis of potent water-soluble tissue transglutaminase inhibitors.
@ast
Synthesis of potent water-soluble tissue transglutaminase inhibitors.
@en
prefLabel
Synthesis of potent water-soluble tissue transglutaminase inhibitors.
@ast
Synthesis of potent water-soluble tissue transglutaminase inhibitors.
@en
P2093
P1476
Synthesis of potent water-soluble tissue transglutaminase inhibitors.
@en
P2093
Alexandre Mongeot
Ian G C Coutts
Richard A Jones
Robert E Saint
Russell Collighan
P304
P356
10.1016/J.BMCL.2008.09.006
P407
P577
2008-09-06T00:00:00Z